Erythrocyte antigen and reticulocyte engraftment after allogeneic hematopoietic stem cell transplantation.
The aim of this study was to study the usefulness of erythrocyte antigen (EA) measurement to study engraftment after allogeneic HSCT. In all, 31 consecutive patients receiving HLA-identical bone marrow (BM) (n=13) or peripheral blood stem cells (n=18) were investigated. Apart from the ABO group, 15 EAs representing six minor blood groups were followed by the simple tube agglutination technique. A total of 20 (64.5%) patients received ABO-identical, eight (25.8%) received ABO minor and three (9.7%) received ABO major mismatched grafts. In all, 29 patients were followed for a median of 12 (6-16) months; 65% of the patients expressed donor type EA 1 month and almost all did so 6 months after transplant. Reticulocyte engraftment was significantly shorter than EA engraftment (median 18 vs 35 days) (P=0.001). Patients who received PB stem cells showed significantly faster EA and reticulocyte engraftment than patients who received BM stem cells (P=0.038 and 0.025). ABO compatibility did not have an impact on reticulocyte and EA engraftment (P=0.4 and 0.55). The earliest donor type EA detected was from the Rh and Kidd system. These data suggest that EA and reticulocyte assays are useful in monitoring engraftment.
Yildirim
I
I
Department of Hematology, Faculty of Medicine, Ankara University, Blood Bank and Apheresis Unit, Ankara, Turkey.
Ozer
Y
Y
Yüksel
M K
MK
Arat
M
M
Arslan
O
O
D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000628:therapy; D000941:Antigens / Q000097:blood* / Q000627:therapeutic use; D001788:Blood Grouping and Crossmatching; D002292:Carcinoma, Renal Cell / Q000628:therapy; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy; D007938:Leukemia / Q000628:therapy; D008297:Male; D008875:Middle Aged; D017701:Reticulocyte Count; D012156:Reticulocytes / Q000637:transplantation*; D033581:Stem Cell Transplantation / Q000379:methods*; D016896:Treatment Outcome
D000941:Antigens